ITEM 1.01 Entry into a Material Definitive Agreement.

On December 19, 2022, ITI Limited, a wholly-owned subsidiary of Intra-Cellular Therapies, Inc. (the "Company"), entered into Amendment No. 1 (the "Amendment") to the Master Services Agreement dated as of January 10, 2017 (the "MSA") by and between Lonza Ltd ("Lonza") and ITI Limited, to, among other items, extend the current term of the MSA until December 31, 2028 and provide for certain minimum annual purchase commitments by the Company for the years 2025 through 2028 for Lonza's manufacture of CAPLYTA.

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be attached as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses